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Guest Editorial
Transforming ras oncogenes and multistage
carcinogenesis
Few topics have caught the imagination of both clinicians and scientists in the field of
cancer research as readily as the recent studies on oncogenes and their role in tumour
development. The first identification of transforming genes in human tumours (Der et
al., 1982; Parada et al., 1982; Santos et al., 1982) was greeted in certain circles with a
response akin to euphoria, accompanied by speculations on the revolutionary
implications for the understanding of human cancer. Predictably, this gave rise to a
backlash of reports of a less optimistic nature which recalled previous
overinterpretations of results in the fields of tumour virology and immunology
(Duesberg, 1983; Rubin, 1984). It is the purpose of this article to review the evidence for
the involvement of transforming genes, particularly those of the ras family, in the
genesis or propagation of human and animal tumours and to discuss the possible stages
of carcinogenesis at which such genes might be implicated.
The molecular genetic analysis of tumour development has been made possible by a
combination of rapid technological progress in molecular biology and the fusion of
ideas and perspectives from the fields of virology and chemical carcinogenesis. The
main focal point of this fusion has been the discovery of proto-oncogenes, the cellular
homologues of the viral genes responsible for the neoplastic properties of cells
transformed by RNA tumour viruses (Bishop, 1981). One of the most exciting
developments was the demonstration that proto-oncogenes could exist in mutated or
activated forms in non-virus-infected cells which had been transformed by chemicals or
isolated from human tumours (Reddy et al., 1982; Tabin et al., 1982; Taparowski et al.,
1982). These revelations came from transfection experiments which utilised the capacity
of cultured embryonic mouse cells (the NIH/3T3 cell) to take up and express the
information encoded in DNA added to the culture medium. It was shown that the
purified DNA from many tumours, but not from the equivalent normal tissues, could
cause morphological transformation of recipient NIH/3T3 cells, and hence must be
qualitatively altered. The proportion of randomly selected human tumours with active
transforming genes is around 10-20% (Santos et al., 1984; Fujita et al., 1984) but this
figure can be much higher in certain experimental animal systems (Balmain et al., 1984;
Sukumar et al., 1983; Guerrero et al., 1984). In the vast majority of cases, the gene
responsible for the transforming properties of DNA from tumours of epithelial,
fibroblastic or haematopoietic origin is a member of the ras family of proto-oncogenes.
Molecular cloning and sequencing of ras genes has identified two regions of the coding
segments which can be activated by point mutations to generate transforming alleles
(Newbold, 1984; Fasano et al., 1984). The frequent occurrence of activated forms of
these genes in human or animal tumours of clonal origin, together with the tantalising
association between carcinogen exposure and the generation of point mutations in
DNA, has inevitably led to speculation that ras genes are intimately involved in human
tumour development.
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Activated oncogenes: cause or effect?
The interpretation that mutations in proto-oncogenes play an important role in the
development of at least some human and animal tumours has been criticised on the
basis that most of the initial results were obtained using cultured tumour cells which
could be subject to secondary changes unrelated to the original transforming event
(Duesberg, 1983; Rubin, 1984). Evidence has been cited that the mutation responsible
for the transforming properties of the Harvey-ras gene in human EJ bladder carcinoma
cells could not be found in at least 70 primary human tumours (Feinberg et al., 1983;
Duesberg, 1983). In retrospect, inspection of the more recent literature indicates that
this unfruitful search is due to the use of molecular probes which would only recognise
mutations of the 12th codon of the H-ras gene. Subsequent studies using restriction
endonucleases and cloned probes which recognise mutations in the Kirsten-ras gene or
at positions 60-62 of the H-ras gene have demonstrated that point mutations can be
detected in - 10% of randomly selected human tumours (Santos et al., 1984; Fujita et
al., 1984). These molecular changes were not detected in normal cells from the same
patients, indicating that the cell populations which contained the mutated sites had
preferentially expanded within the original tumours. This of course does not prove that
the initial mutation "caused" the selective amplification of the target cell, but when
taken in conjunction with the evidence showing that ras genes can acquire the ability to
transform cells in vitro as a direct result of such mutations, the arguments in favour of
involvement become much more than circumstantial.
In any case, even if proto-oncogene modification by mutation, translocation or
amplification is a consequence of an unrelated initial transforming event this does not
necessarily mean that such modifications are irrelevant in terms of neoplastic
development. Because of the multistage nature of carcinogenesis it is possible that
mutation or translocation of an oncogene, as a result possibly of replication errors
during the rapid cell proliferation of the pre-neoplastic phase, could contribute to the
development of a more malignant phenotype and thus "cause" tumour progression. An
example of this is the African type of Burkitt's lymphoma, which is characterised by
chronic proliferation of the pre-neoplastic B cells owing to prior infection and
immortalisation by Epstein-Barr virus (Klein, 1984). Such a highly hyperplastic state
appears to provide the correct milieu for activation of the c-myc gene by one of the
typical translocations observed in Burkitt's lymphomas. Thus, although the
juxtaposition of c-myc with one of the immunoglobulin genes by translocation may not
be the primary initiating event in lymphomagenesis, the evidence that virtually all
examples of Burkitt's lymphoma exhibit one of the three characteristic translocations
(Klein, 1984) together with more recent information on the role of c-myc expression in
the mammalian cell cycle (Armelin et al., 1984) provides a very strong case for a crucial
role for this oncogene in determining the neoplastic phenotype.
Multiple routes to transformation by ras genes
Given that there are at least three members of the ras gene family, each of which can be
activated by different mutations at positions 12 or 61, it has been calculated that the
number of potential mutations which can give rise to transforming ras gene products is
42 (Santos et al., 1984). This figure may represent only the tip of the iceberg, since it is
conceivable that mutations at positions other than 12 or 61 may exist in tumours which
do not have dominant transforming genes detectable by the NIH/3T3 transfectionGUEST EDITORIAL 3
assay. Indeed, in vitro mutagenesis studies have demonstrated the existence of
"hot-spots" for mutational activation of the transforming potential of ras genes.
These are located, as expected, around positions 12 and 61, but extend to
neighbouring codons from these two central positions (Fasano et al., 1984; see also
Marshall et al., 1984). Interestingly, the transforming capacity of mutations in some of
these peripheral sites is not as high as at codons 12 or 61. This may support the
suggestion that primary tumours with mutatiolis at these other positions could score as
negative in NIH/3T3 transfections. It will be necessary to develop alternative assays,
possibly using more appropriate target cells as recipients for transfected DNA, to
determine whether such weakly transforming genes are also present in primary tumours.
The impression should however not be given that alteration of coding potential by
mutation is the only means by which proto-oncogenes may be activated in tumours.
Aberrant regulation of the normal gene during the cell cycle or a quantitative increase
in its level of expression could also be important. Evidence in favour of the latter
possibility comes from experiments in which a transcriptional enhancer was attached to
the normal human Harvey-ras gene. Transfection of this "upregulated" gene into
fibroblast cells led to the appearance of morphologically transformed foci (Chang et al.,
1982).
Similar upregulation of a gene which is in addition mutated at codon 12 has even
more potent effects. Spandidos & Wilkie (1984) have shown that the combination of
mutation and transcriptional elevation of the Harvey-ras gene is sufficient to transform
primary rodent cells. Cloned ras genes with only one of these modifications do not have
this capacity, but can only transform cells which have previously been "immortalised"
and are established in culture (Newbold & Overell, 1983; Ruley, 1983; Land et al.,
1983).
The observation that a single ras oncogene, albeit one which is highly streamlined by
genetic manipulation, can transform primary cells, appears at first glance to contradict
the results of Land et al. (1983). These authors introduced a concept of cooperating
oncogenes which was comforting in its simplicity: the multistage nature of
carcinogenesis necessitates the involvement of multiple oncogenes. In support of this
idea, it was shown that while ras genes with only a single point mutation could not
transform primary cells, provision of the v-myc gene in co-transfection experiments did
lead to complete transformation. How might a single, upregulated ras gene achieve the
same effects? One possible rationalisation may lie in the observation that primary cells
which are fully transformed by the transcriptionally enhanced, mutated gene display a
variety of chromosomal aberrations (Spandidos & Wilkie, 1984). It is conceivable that
these secondary chromosomal changes might lead to the activation of an additional
gene which complements the function of the ras protein, completing the transformation
process.
Ras gene activation: early, late, or both?
It has been postulated that the acquisition of dominant transforming properties by
point mutation of ras genes may be a relatively late event in tumorigenesis. This was
based on the fact that NIH/3T3 cells are already initiated or partially transformed, and
may require only a "late" event for completion of the route to malignancy. In
agreement with this interpretation, dominant transforming ras genes have been detected
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al., 1984) and in a spontaneously arising metastatic variant of a T cell lymphoma
(Vousden & Marshall, 1984). This suggests that the acquisition of more malignant
properties, which frequently occurs after prolonged passage of cells in culture, may be
associated with activation of a member of this gene family.
Evidence that ras gene activation is not always a late event in tumour development
comes from animal model systems in which different stages of tumour progression have
been identified. The induction of tumours in mouse skin by treatment with chemical
carcinogens is a stepwise process characterised by the appearance of multiple
papillomas, only a small percentage of which progress to form malignant lesions (Burns
et al., 1978). It has recently been demonstrated that the cellular Harvey-ras gene is
reproducibly activated in this system, since skin tumour DNAs have the capacity to
transform NIH/3T3 cells in transfection assays (Balmain & Pragnell, 1983; Balmain et
al., 1984). The activation of the oncogene, however, did not correlate with the
development of malignancy, since the premalignant papillomas had the same
transforming ability as invasive carcinomas (Balmain et al., 1984). This result is perhaps
not so surprising, since papillomas can be autonomous lesions which proliferate rapidly
and reach a substantial size. Tumour cells with similar properties but located in tissues
such as dermis, brain or bone marrow could have much more serious consequences for
the host since they may not be contained within the normal geographical boundaries
imposed by epithelial tissue organisation (Cairns, 1975). In other words, the number of
"events" required to generate a skin papilloma, formally classified as benign, may be
similar to that required for, say, a fibrosarcoma or a leukaemia, each of which could
kill the host animal. In agreement with this interpretation, analysis of age-incidence
curves for different cancers in humans has suggested that the total number of events
required for carcinoma formation may be greater than for many other types of tumour
(Peto, 1977). This may ultimately mean that the staging of tumours classically carried
out on the basis of cellular morphology and the relationship to surrounding tissues may
acquire a new dimension as the molecular analysis of genetic events in tumorigenesis
proceeds.
Are point mutations in ras genes caused by direct interaction with carcinogens?
While the dramatic effect of point mutations on the transforming activity of ras genes
and the capacity of carcinogens to induce these lesions in vitro (Marshall et al., 1984) is
suggestive of a causal link, direct evidence that the mutations are induced by carcinogen
treatment in vivo is still lacking. Indirect evidence can be adduced from recent studies
on thymoma formation after treatment of mice with chemical carcinogens of X-rays.
Guerrero et al. (1984) demonstrated that in chemical carcinogen-induced tumours, the
N-ras gene was activated and could transform 3T3 cells by transfection. In the
radiation-induced tumours, the Kirsten-ras gene was the only positive transforming
gene detected. This intriguing dependence of the activated oncogene on the type of
inducing agent might indicate a direct interaction between carcinogen and target gene.
However, further studies will be necessary to eliminate the alternative possibility that
different target cell populations are being transformed by the two agents, despite the
fact that the tumours are histologically identical.
Transforming ras genes have also been detected in rat mammary carcinomas induced
by treatment with nitroso-methylurea (NMU) (Sukumar et al., 1983). One of the NMU-
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transition at the 12th codon, resulting in the replacement of glycine with glutamic acid
in the p21 protein product. This particular mutation happens to be that predicted on
the basis of direct interaction between NMU and cellular DNA, which, as a result of
alkylation of deoxyguanosine residues, leads to mispairing during replication and
transition mutations (Margison & O'Connor, 1978). Sukumar et al., 1984 consequently
suggested that the oncogene activation may be directly linked to the interaction of
NMU with the DNA, particularly since restriction analysis of DNAs from a series of
mammary carcinomas induced by the same carcinogen indicated the presence of
mutations which were similar, and possibly identical, to that determined by sequence
analysis. What appears to be a more heterogeneous pattern is emerging from our
studies on mouse skin tumours initiated by treatment with dimethylbenzanthracene
(DMBA) and promoted with 12-0-tetradecanoyl-phorbol-13-acetate (TPA). Analysis of
the p21 proteins encoded by the activated Harvey-ras genes of these tumours has
identified at least 3 different forms of p21 which presumably arise by different
mutations (M. Quintanilla & A. Balmain, unpublished results). This shows that the
genetic changes which take place in tumours initiated by DMBA are not always
identical, although it remains possible that all of the mutations are nevertheless caused
by direct interaction between the carcinogen and the cellular H-ras gene. Detailed
sequence analysis will be required to determine whether these mutations are of the
transversion type commonly induced, at least in bacterial systems, by carcinogenic
aromatic hydrocarbons (Eisenstadt et al., 1982).
How do activated ras genes transform cells?
The presence of activated ras genes in so many different human and animal tumours
has stimulated an intensive effort to determine the biological role of ras p21 proteins in
tumour development. Among the biological properties commonly associated with
transformation are morphological changes, immortalisation and aberrant growth factor
control of cell proliferation. Interestingly, all of these properties have been associated
with the activation or elevated expression of ras genes (Spandidos & Wilkie, 1984; Land
et al., 1983; Newbold & Overall, 1983; Marshall, 1984). A link between ras gene
activation and immortalisation was obtained in experiments where the mutated form of
human Harvey ras or the normal ras in the presence of transcriptional enhancers, was
found to immortalise primary rodent cells (Spandidos & Wilkie, 1984). However,
immortalisation is undoubtedly a complex phenomenon which can involve recessive
lesions in a number of different genes (Pereira-Smith & Smith, 1983). Although the
immortalisation phenotype can be induced by transfection of primary rodent cells with
cloned segments of polyoma (Rassoulzadegan et al., 1983) or Epstein-Barr DNA viruses
(Griffin & Karran, 1984), infection of primary cells with retroviruses which contain
both activated ras genes and transcriptional enhancers has not to date had the same
effects (Kaplan & Ozanne, 1983; Marshall, 1984). At the very least, experiments which
have been stimulated by these apparent contradictions should lead to their eventual
resolution and to clearer definitions of what takes place at this important stage of
carcinogenesis.
The recent discovery of a GTPase activity in normal p21 molecules which is impaired
after mutation of codon 12 represents the first biochemical demonstration of a
functional difference between normal and activated forms of the protein (McGrath et
al., 1984). The significance of this activity lies in the analogy with the "G proteins"6 GUEST EDITORIAL
which, like p21, have guanine nucleotide binding capacity and can hydrolyse GTP to
GDP, but in addition are known to function as intracellular transducers of growth
regulatory signals from cell surface receptors (Gilman, 1984; Newbold, 1984). Whether
P21 ras fulfils a similar role remains to be established. In any case, these results extend
the link with growth factor activity which was previously noted in studies on secretion
of transforming growth factors by sarcoma virus transformed cells (DeLarco & Todaro,
1978; Ozanne et al., 1980).
In conclusion, there is strong evidence that ras-gene activation is important in the
genesis of at least some human and animal tumours, but the precise stage at which the
genes become activated and the resultant biological consequences for the cell are still
unclear. In some systems, for example mouse skin carcinogenesis, the activation is
obviously a relatively early event and may therefore be a necessary but not sufficient
condition for malignancy. It has also been observed that cell lines derived from one of
five metastatic deposits of malignant melanoma in a single patient have activated ras
oncogenes (Albino et al., 1984). This, together with the activation of Kirsten-ras in a T-
cell lymphoma during passage in culture (Vousden & Marshall, 1984) may constitute
examples of systems in which ras gene activation is a late event which might
nevertheless contribute to the evolution of variant cell populations within a developing
tumour. It is perhaps not so surprising in view of the multifaceted nature of tumour
development that different experimental systems can give different results. The primary
biological features which characterise the neoplastic phenotype - immortalisation,
anchorage-independent growth and metastatic capacity - are also highly independent
variables in different individual tumours (Foulds, 1969) and it would therefore be naive
to expect complete consistency in the chronological order of molecular events leading to
neoplasia. As is often the case in biology, cells, in particular tumour cells, may turn out
to have a surprisingly broad capacity to reach the same end-point by a variety of
different routes.
A. Balmain
Beatson Institute for Cancer Research
Garscube Estate, Switchback Rd, Bearsden, Glasgow G61 1BD, UK.
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